89bio Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.
IPO Year: 2019
Exchange: NASDAQ
Website: 89bio.com
Recent Analyst Ratings for 89bio Inc.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/14/2025 | $11.00 | Neutral | Goldman |
3/13/2025 | $25.00 | Buy | Citigroup |
2/4/2025 | Outperform | Wolfe Research | |
4/22/2024 | $30.00 | Buy | BofA Securities |
1/12/2024 | $24.00 → $15.00 | Outperform → Sector Perform | RBC Capital Mkts |
10/10/2023 | Outperform → Perform | Oppenheimer | |
8/28/2023 | $36.00 | Buy | UBS |
6/13/2023 | $49.00 | Outperform | Evercore ISI |
5/12/2022 | $33.00 → $12.00 | Outperform → Strong Buy | Raymond James |
12/20/2021 | $46.00 | Buy | HC Wainwright & Co. |
89bio Inc. Press Releases
Fastest customizable press release news feed in the world
89bio to Participate in the Leerink Partners Global Healthcare Conference
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 10, 2025 at 4:20 PM EST and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible in the investor section of 89bio's website. A replay of the webcast will be available for approximately 30 days following the conference. Abou
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline histology data expected in 1H 2027 and 2028, respectively – –The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) will be unblinded after study completion at Week 52 vs. Week 26 following discussions with the U.S. Food and Drug Administration (FDA); topline data are now expected in 1Q 2026 – – Cash, cash equivalents, and marketable securities totaled $440.0 million as of December 31, 2024; a follow-on offering in the 1Q 2025 resulted in gross proceeds of $287.
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 163,650 shares of the Company's common stock to seven new employees (the "Inducement Grants") on January 31, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the "Plan"). The Inducement Grants wer
89bio Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. ("89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it closed its previously announced underwritten public offering of 25,957,142 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 4,285,714 shares, at a public offering price of $8.75 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 6,900,000 shares of its common stock, at a purchase price of $8.749
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. ("89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its previously announced upsized underwritten public offering of 21,671,428 shares of its common stock at a public offering price per share of $8.75 and, in lieu of common stock to a certain investor, pre-funded warrants to purchase up to 6,900,000 shares of its common stock at a public offering price of $8.749. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immedia
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. ("89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, 89bio is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $37.5 million of shares of its common stock at the public
89bio Provides Business Update and Outlook for 2025
– Completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG); topline 26-week data expected in the second half of 2025 – – The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continues to enroll patients across both trials – – Cash, cash equivalents, and marketable securities totaled approximately $440 million as of December 31, 2024 – SAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatmen
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 48,000 shares of the Company's common stock to one new employee (the "Inducement Grant") on December 13, 2024 (the "Grant Date"). The Inducement Grant has been granted pursuant to the Company's 2023 Inducement Plan (the "Plan"). The Inducement Grant was grante
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 49,800 shares of the Company's common stock to four new employees (the "Inducement Grants") on November 25, 2024 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the "Plan"). The Inducement Grants were
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 8:20 AM ET and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible in the investor section of 89bio's website. A replay of the webcast will be available for approximately 30 days following the conference.
89bio Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Goldman initiated coverage on 89bio with a new price target
Goldman initiated coverage of 89bio with a rating of Neutral and set a new price target of $11.00
Citigroup initiated coverage on 89bio with a new price target
Citigroup initiated coverage of 89bio with a rating of Buy and set a new price target of $25.00
Wolfe Research initiated coverage on 89bio
Wolfe Research initiated coverage of 89bio with a rating of Outperform
BofA Securities resumed coverage on 89bio with a new price target
BofA Securities resumed coverage of 89bio with a rating of Buy and set a new price target of $30.00
89bio downgraded by RBC Capital Mkts with a new price target
RBC Capital Mkts downgraded 89bio from Outperform to Sector Perform and set a new price target of $15.00 from $24.00 previously
89bio downgraded by Oppenheimer
Oppenheimer downgraded 89bio from Outperform to Perform
UBS initiated coverage on 89bio with a new price target
UBS initiated coverage of 89bio with a rating of Buy and set a new price target of $36.00
Evercore ISI initiated coverage on 89bio with a new price target
Evercore ISI initiated coverage of 89bio with a rating of Outperform and set a new price target of $49.00
89bio upgraded by Raymond James with a new price target
Raymond James upgraded 89bio from Outperform to Strong Buy and set a new price target of $12.00 from $33.00 previously
HC Wainwright & Co. initiated coverage on 89bio with a new price target
HC Wainwright & Co. initiated coverage of 89bio with a rating of Buy and set a new price target of $46.00
89bio Inc. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Director Ra Capital Management, L.P. bought $49,999,994 worth of shares (5,714,285 units at $8.75) (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Director Mcwherter Charles bought $99,850 worth of shares (15,000 units at $6.66), increasing direct ownership by 150% to 25,000 units (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Chief Executive Officer Palekar Rohan bought $39,450 worth of shares (5,000 units at $7.89), increasing direct ownership by 1% to 471,236 units (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Director Mcwherter Charles bought $80,000 worth of shares (10,000 units at $8.00) (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Chief Executive Officer Palekar Rohan bought $83,500 worth of shares (10,000 units at $8.35), increasing direct ownership by 2% to 466,236 units (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Ra Capital Management, L.P. bought $20,722,500 worth of shares (1,350,000 units at $15.35) (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
89bio Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Officer Le-Nguyen Quoc was granted 14,750 shares and covered exercise/tax liability with 1,050 shares, decreasing direct ownership by 0.30% to 343,652 units (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Chief Financial Officer Martins Ryan covered exercise/tax liability with 780 shares, decreasing direct ownership by 0.29% to 269,674 units (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Chief Medical Officer Mansbach Harry H covered exercise/tax liability with 1,050 shares, decreasing direct ownership by 0.33% to 318,834 units (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Chief Executive Officer Palekar Rohan covered exercise/tax liability with 3,249 shares, decreasing direct ownership by 0.38% to 862,240 units (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Chief Financial Officer Martins Ryan covered exercise/tax liability with 3,828 shares, decreasing direct ownership by 1% to 270,454 units (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Officer Le-Nguyen Quoc covered exercise/tax liability with 3,793 shares, decreasing direct ownership by 1% to 344,702 units (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Chief Executive Officer Palekar Rohan covered exercise/tax liability with 8,946 shares, decreasing direct ownership by 1% to 864,692 units (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Chief Medical Officer Mansbach Harry H covered exercise/tax liability with 3,817 shares, decreasing direct ownership by 1% to 319,884 units (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
SEC Form 4 filed by Director Ra Capital Management, L.P.
4 - 89bio, Inc. (0001785173) (Issuer)
SEC Form 4 filed by Director Laporte Kathleen
4 - 89bio, Inc. (0001785173) (Issuer)
89bio Inc. SEC Filings
Amendment: SEC Form SCHEDULE 13D/A filed by 89bio Inc.
SCHEDULE 13D/A - 89bio, Inc. (0001785173) (Subject)
SEC Form S-8 filed by 89bio Inc.
S-8 - 89bio, Inc. (0001785173) (Filer)
SEC Form 10-K filed by 89bio Inc.
10-K - 89bio, Inc. (0001785173) (Filer)
89bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
8-K - 89bio, Inc. (0001785173) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by 89bio Inc.
SCHEDULE 13G/A - 89bio, Inc. (0001785173) (Subject)
Amendment: SEC Form SCHEDULE 13G/A filed by 89bio Inc.
SCHEDULE 13G/A - 89bio, Inc. (0001785173) (Subject)
Amendment: SEC Form SCHEDULE 13G/A filed by 89bio Inc.
SCHEDULE 13G/A - 89bio, Inc. (0001785173) (Subject)
SEC Form 8-K filed by 89bio Inc.
8-K - 89bio, Inc. (0001785173) (Filer)
Amendment: SEC Form SCHEDULE 13D/A filed by 89bio Inc.
SCHEDULE 13D/A - 89bio, Inc. (0001785173) (Subject)
SEC Form 8-K filed by 89bio Inc.
8-K - 89bio, Inc. (0001785173) (Filer)
89bio Inc. Leadership Updates
Live Leadership Updates
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, effective today. Dr. Perney brings an extensive track record of expertise and leadership in Regulatory, Product Development and Quality in the industry to the Company. "We are delighted to welcome Dr. Teresa Perney to our executive leadership team at this critical juncture for 89bio," said Rohan Palekar, CEO of 89bio. "As we advance pegozafermin through
89bio Appoints Francis Sarena as Chief Operating Officer
SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Francis Sarena as Chief Operating Officer, effective August 5, 2024. "We are excited to welcome Francis to our executive team at this pivotal growth phase for 89bio," said Rohan Palekar, CEO of 89bio. "As we advance our Phase 3 clinical program for pegozafermin and prepare for scale up, Francis' extensive strategic, operational, business development and leadership expertise will be immensely valuable. His prov
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
SAN FRANCISCO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Dr. Charles McWherter to its Board of Directors, effective July 30, 2024. Dr. McWherter most recently served as Chief Scientific Officer and President of Research and Development of CymaBay Therapeutics until it was acquired by Gilead Sciences in March 2024. "We are thrilled to welcome Charles, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, CEO of 89bio. "His expertise in drug dev
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Martin Babler to its Board of Directors, effective April 13, 2024. Mr. Babler, a highly successful executive who brings valuable industry experience to 89bio, currently serves as President, Chief Executive Officer and Chairman of the Board of Alumis Therapeutics. "As 89bio executes on its ongoing Phase 3 programs for pegozafermin, this is an opportune time to add an industry leader like Martin to our board,"
89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors
SAN FRANCISCO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors. Dr. Atkinson currently serves as Senior Vice President, Head of Commercial Manufacturing and Supply Chain of Vertex Pharmaceuticals. "As a seasoned biopharmaceutical industry veteran with deep-rooted expertise, Morrey is a welcome addition to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Morrey brings extensive knowledge
89bio Announces Appointment of Kathy LaPorte to its Board of Directors
SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Kathy has a strong track record for enhancing operational capabilities to drive growth. Her extensive experien
89bio Inc. Financials
Live finance-specific insights
89bio's Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks
- 44mg Q2W dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 24% on NASH resolution without worsening of fibrosis (p=0.0005) - - 30mg QW dose had a placebo-adjusted effect size of 19% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 21% on NASH resolution without worsening of fibrosis (p=0.0009) - - 44mg Q2W and 30mg QW doses had at least one-stage fibrosis improvement without worsening of NASH at 3.5 times placebo rate and NASH resolution without worsening of fibrosis at 12 to 14 times placebo rate - - Every-two-week dose data reinforces pegozafermin's pot
89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
- Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p<0.001) in triglycerides (TG) from baseline; results were consistent in patients on or not on background therapy - - Observed significant and potent reductions in atherogenic lipids (non-HDL-C and apo B), liver fat, and improvements in liver enzymes and glycemic control markers - - ENTRIGUE results support 89bio's transition to a late-stage development company; Phase 3 expected to initiate in first half of 2023 - - Conference call and webcast today at 1:30 p.m. PST/4:30 p.m. EST - SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- 89bio, In
Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update
- Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 – - $142.5 million in cash and cash equivalents expected to provide runway into the second half of 2023 – - Appointment of Rohan Palekar to Board of Directors – - Company to host conference call today, March 1, 2022 at 1:30 p.m. PT / 4:30 p.m. ET – SEATTLE, March 01, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the year ended December 31, 2021.
89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH
63% of patients achieved 2-point or greater improvement in NAS without worsening of fibrosis; clinically meaningful improvements on registration enabling endpoints of NASH resolution (32%) and fibrosis improvement (26%)Robust changes on multiple non-invasive liver tests, markers of cardiovascular health and glycemic control support pegozafermin's potential as a compelling treatment option for NASH Phase 2b ENLIVEN trial ongoing in NASH patients with results expected in first half 2023Conference call and webcast today at 1:30 p.m. PST/4:30 p.m. EST SAN FRANCISCO, Jan. 24, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the developm
89bio Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
Amendment: SEC Form SC 13D/A filed by 89bio Inc.
SC 13D/A - 89bio, Inc. (0001785173) (Subject)
Amendment: SEC Form SC 13G/A filed by 89bio Inc.
SC 13G/A - 89bio, Inc. (0001785173) (Subject)
Amendment: SEC Form SC 13G/A filed by 89bio Inc.
SC 13G/A - 89bio, Inc. (0001785173) (Subject)
Amendment: SEC Form SC 13G/A filed by 89bio Inc.
SC 13G/A - 89bio, Inc. (0001785173) (Subject)
Amendment: SEC Form SC 13G/A filed by 89bio Inc.
SC 13G/A - 89bio, Inc. (0001785173) (Subject)
Amendment: SEC Form SC 13G/A filed by 89bio Inc.
SC 13G/A - 89bio, Inc. (0001785173) (Subject)
Amendment: SEC Form SC 13D/A filed by 89bio Inc.
SC 13D/A - 89bio, Inc. (0001785173) (Subject)
SEC Form SC 13D/A filed by 89bio Inc. (Amendment)
SC 13D/A - 89bio, Inc. (0001785173) (Subject)
SEC Form SC 13G/A filed by 89bio Inc. (Amendment)
SC 13G/A - 89bio, Inc. (0001785173) (Subject)
SEC Form SC 13G/A filed by 89bio Inc. (Amendment)
SC 13G/A - 89bio, Inc. (0001785173) (Subject)